Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day... Show more
Organon & Co. (NYSE: OGN), a global healthcare company dedicated to women's health and biosimilars, is exhibiting signs of a strengthening uptrend as one of the top monthly gainers in the pharmaceuticals sector. Organon & Co (OGN, $8.43) was one of the top gainers for the month, rising +17.57% to $8.43 per share. A.I.dvisor analyzed 59 stocks in the Pharmaceuticals: Major Industry for the month ending January 13, 2026 and discovered that 45 of them (76.47%) exhibited an Uptrend while 14 of them (23.53%) exhibited a Downtrend. This broad industry positivity aligns with OGN's momentum, having rallied approximately 15% throughout 2025 despite challenges, reflecting investor confidence in its expanding biosimilars portfolio and women's health focus. The company's pipeline advancements and acquisitions position OGN for potential continued uptrend growth in 2026 amid increasing demand for affordable biologic therapies.
Key Takeaways
Organon & Co. focuses on delivering impactful medicines and solutions for women's health, biosimilars, and established brands across therapeutic areas like reproductive health, cardiovascular disease, and oncology. Its core offerings include over 70 products, such as contraceptives, fertility treatments, and biosimilars to high-cost biologics, emphasizing accessibility and innovation. The company provides comprehensive support through education programs, access initiatives, and partnerships to improve patient outcomes globally, serving markets in over 140 countries with a commitment to sustainability and equity in healthcare.
In 2025, Organon & Co. introduced several new biosimilars and expanded its portfolio through acquisitions. In November, the FDA approved POHERDY (pertuzumab-dpzb), the first biosimilar to PERJETA for HER2-positive breast cancer treatments. September saw European Commission approvals for BILDYOS (denosumab) and BILPREVDA (denosumab), biosimilars to PROLIA and XGEVA, respectively, for bone health conditions. In April, Organon acquired U.S. rights to Tofidence (tocilizumab-bavi), a biosimilar to ACTEMRA for autoimmune diseases. Additionally, the acquisition of Dermavant in October 2024 brought VTAMA (tapinarof) cream into the fold, a topical treatment for psoriasis, with advancements in its application for women's health dermatology needs.
Complementing OGN's uptrend analysis are advanced tools like Tickeron's AI trading bots, which provide sophisticated insights for investors. Tickeron's platform features AI-powered trading robots, virtual agents for stocks and ETFs, and single-ticker AI Trading Agents that are fully hedged with inverse ETFs for risk management. These bots use machine learning to deliver real-time signals, smart money management, and stock forecasts, with some achieving returns up to 158% in sectors like aerospace, mining, and ETFs. Tools such as A.I.dvisor, which analyzed OGN's monthly gain, scan historical patterns to predict outcomes, offering backtested algorithms for strategies like day trading on 60-minute intervals. With no prior trading experience required, these bots alert users to buys, sells, potential profits, and stop losses, making them valuable for spotting opportunities in stocks like OGN during uptrends.
On June 04, 2026, the Stochastic Oscillator for OGN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The Momentum Indicator moved above the 0 level on June 10, 2026. You may want to consider a long position or call options on OGN as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OGN advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 200 cases where OGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for OGN moved out of overbought territory on June 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
OGN broke above its upper Bollinger Band on June 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.906) is normal, around the industry mean (19.503). P/E Ratio (14.441) is within average values for comparable stocks, (25.855). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.650). OGN has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.032). OGN's P/S Ratio (0.569) is slightly lower than the industry average of (3.885).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsMajor